Ifosfamide chemotherapy for pancreatic carcinoma

Research output: Contribution to journalArticle

13 Scopus citations


From April 1982 through February 1984, 29 patients with pancreatic cancer were treated with ifosfamide (1.25-1.5 g/m2 on days 1-5) +N-acetylcysteine (NAC) 2 g p.o. every 6 h on days 1-7 every 3 weeks. In responding patients without serious toxicity, subsequent courses of ifosfamide were escalated every 3 weeks by 0.25 g/m2 per day to a maximum of 2 g/m2 per day, with escalation of NAC to 12 g/day. Patients with KPS<50, serum creatinine or bilirubin>2 mg/d l, or obstructive uropathy were ineligible. The median age was 54 (range 36-78), median KPS 70, and median pretreatment weight loss 9 kg. Toxicity included nausea, vomiting, moderate myelosuppression, and occasional mental confusion. Hematuria (>11 RBC/HPF) developed in only 1/29 courses (17 patients) of ifosfamide at ≥1.75 g/m2 per day, and in 7/52 courses (27 patients) overall (13%). Of 27 evaluable patients 6 responded (22%), including 1 with complete response. The median survival was 6 months. Based upon these results, we are currently evaluating ifosfamide + 5-fluorouracil in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)S51-S54
JournalCancer Chemotherapy and Pharmacology
Issue number2 Supplement
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Ifosfamide chemotherapy for pancreatic carcinoma'. Together they form a unique fingerprint.

  • Cite this